Les Laboratoires Pierre Fabre and XtalPi announced a collaboration to discover new clinical candidates. XtalPi will apply its AI‑enabled platform and robotics to design novel small‑molecule drugs against undisclosed targets. Pierre Fabre will provide medical biology, pre‑clinical and translational expertise and will handle later clinical development and commercialization. The deal includes an upfront payment, milestone payments and downstream profit sharing, though the amounts were not disclosed.
Why it matters
If successful, the partnership could speed up the delivery of new cancer therapies for patients with unmet medical needs.
